COULD ANAEMIA BE CONSUMING YOUR CKD PATIENTS?

Anaemia is a common comorbidity of Chronic Kidney Disease (CKD), affecting one in five patients.1 Several studies have shown that anaemia can have serious consequences for health and quality of life for patients.2-6

At Astellas, we strive to improve the health of people all over the world and to find better solutions to diseases and conditions, where there are unmet needs. And we consider this to be the case within nephrology – in particular when it comes to anaemia of CKD.

We want to take the opportunity to provide more information about anaemia of CKD and give you a chance to test your knowledge with a short quiz.

To stay updated on developments within anaemia of CKD, please sign up below, for more information.

Astellas
Changing tomorrow

 

TAKE THE CHALLENGE AND GAIN NEW INSIGHTS ABOUT ANAEMIA AND CKD PATIENTS

Background for the quiz

Anaemia could be consuming patients with advanced CKD. Not only in terms of physical impact, such as serious CV complications, but also in terms of impared quality of life.

The questions in this quiz are based on the findings in published studies.2,7,8

DO YOU WANT TO RECEIVE MORE INFORMATION WITHIN THE

FIELD OF NEPHROLOGY AND ANAEMIA OF CKD?

EXPOSING THE RISKS OF ANAEMIA IN CKD

How great is the CV risk in CKD patients?


See what impact anaemia of CKD can have on patients


The role of the HIF pathway 

References: 

1. Dmitrieva O, de Lusigan S, Macdougall IC, Galagher H, Tomson C, Harris K, et al. Association of anaemia in primary care patients with chronic kidney disease: cross sectional study of quality improvement in chronic kidney disease (QICKD) trial data. BMC Nephrol. 2013;25:14-24.

2. Astor BC, Coresh J, Heiss G, Pettitt D, Mark MS, and Sarnak J. Kidney Function and Anemia as Risk Factors for Coronary Heart Disease and Mortality: The Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 2006;151(2):492-500.

3. Weiner DE, Tighiouart H, Vlagopoulos PT, Griffith JL, Salem DN, Levey AS, et al. Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol. 2005;16(6):1803-10.

4. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Lambers Heerspink HJ, Mann JF, et al. Chronic kidney disease and cardiovascular Risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382:339–52.

5. Eckardt KU. Anaemia in end-stage renal disease: pathophysiological considerations. Nephrol Dial Transplant. 2001;16(Suppl 7):2-8.6. Mohanram A, Zhang Z, Shahinfar S, Keane WF, Brenner BM, and Toto RD. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Intl. 2004;66:1131-38.

6. Mohanram A, Zhang Z, Shahinfar S, Keane WF, Brenner BM, and Toto RD. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Intl. 2004;66:1131-38.

7. Evans M, Bower H, Cockburn E, Jacobson SH, Barany P and Carreri JJ. Contemporary management of anaemia, erythropoietin resistance and cardiovascular risk in patients with advanced chronic kidney disease: a nationwide analysis. Clin Kidney J. 2020;May:1-7.

8. Eriksson D, Goldsmith D, Teitsson S, Jackson J and van Nooten F. Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia. BMC Nephrol. 2016;17(1):97.